http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-582667-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aaacf277d1ca555b6a99ad72dec179b3 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 |
| filingDate | 2007-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85606e3513def2ab7888acf8082c23b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d14d9d5657a3c41c8bcbacbbd5d9252f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9da3069bde290eddbbad6bbf9118e753 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7eeb749183265c8ee5828689a15b225a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fb63a697ee0b6592b546464f07dde8a |
| publicationDate | 2012-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-582667-A |
| titleOfInvention | Combination of an HMG-CoA reductase inhibitor and a colloidal clay, and method for the preparation thereof |
| abstract | Disclosed is a pharmaceutical composition for oral administration comprising Atorvastatin or a pharmaceutical acceptable salt thereof, as an active ingredient, and an effective amount of Attapulgite as a stabilizer to inhibit hydrolysis and/or isomerization and/or elimination and/or oxidation and/or re-, crystallization, wherein said composition is prepared with direct compression and said composition comprises 3% to 10% by weight of said Atorvastatin or salt thereof, wherein said composition does not comprise any buffering or alkaline agent. A process for the preparation of a solid dosage form for oral administration such as a tablet, capsule or sachet containing Atorvastatin, or a pharmaceutical acceptable salt thereof, as an active ingredient and an effective amount of Attapulgite as a stabilizer to inhibit isomerization and/or elimination and/or oxidation and/or re-crystallization wherein is said solid dosage form comprises 3% to 10% by weight of said Atorvastatin or salt thereof is also disclosed, wherein the process comprises the steps of:(a) forming a homogenous mixture by mixing the total quantity of said active ingredient with a portion of the total quantity of Attapulgite and at least one optional excipient such as a binder, a diluent, a disintegrant and/or a glidant and mixing until uniform;(b) sieving the above mixture through a sieve; (c) adding to the sieved mixture the total quantities of at least one optional excipient such as a binder, a diluent, a disintegrant and/or a glidant and mixing until uniform; (d) admixing the remaining portion of the total quantity of Attapulgite and mixing until uniform; (e) subsequently adding a lubricant and forming a homogenous mixture, and (f) formulating the resulting mixture in a solid dosage form either by compressing it into a desired tablet form or by filling capsules or sachets. |
| priorityDate | 2007-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.